Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan 0.01% in ocular hypertensive or glaucomatous patients
2017-000846-23Phase 3Completed
- Sponsor
- Laboratoires Théa
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimatoprost in ocular hypertension and Glaucoma (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Change in intraocular pressure from baseline to Week 12. Started Jul 2018; status: completed.
02
Drugs
bimatoprost
03
Conditions
ocular hypertensionGlaucoma
Beyond the preview
Go deeper on 2017-000846-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000846-23.